Comprehensive screening for naturally occurring hepatitis c virus resistance to direct-acting antivirals in the NS3, NS5A, and NS5B genes in worldwide isolates of viral genotypes 1 to 6

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 4, 2016, Pages 2402-2416

  Patiño Galindo, Juan Ángel ^a,c   Salvatierra, Karina ^a,b,d   González Candelas, Fernando ^a,c   López Labrador, F Xavier ^a,b,c  

^a UNIVERSITY OF VALENCIA   (Spain)

^b Generalitat Valenciana   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSIDAD NACIONAL DE MISIONES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ASUNAPREVIR; BOCEPREVIR; DACLATASVIR; LEDIPASVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; OMBITASVIR; TELAPREVIR; NS-5 PROTEIN, HEPATITIS C VIRUS; NS3 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

ANTIVIRAL RESISTANCE; ARTICLE; GENOTYPE; HAPLOTYPE; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 6; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; NONHUMAN; PRIORITY JOURNAL; VIRUS GENE; VIRUS GENOME; CHROMOSOMAL MAPPING; DRUG EFFECTS; GENETIC POLYMORPHISM; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMAN; ISOLATION AND PURIFICATION; MISSENSE MUTATION; VIROLOGY;

ANTIVIRAL AGENTS; CHROMOSOME MAPPING; DRUG RESISTANCE, VIRAL; GENOME, VIRAL; HAPLOTYPES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MUTATION, MISSENSE; POLYMORPHISM, GENETIC; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84963736042     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02776-15     Document Type: Article

References (45)

1. Hajarizadeh B, Grebely J, Dore GJ. 2013. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 10:553-562. http://dx.doi.org/10.1038/nrgastro.2013.107.
2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. 2013. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:1333-1342. http://dx.doi.org/10.1002/hep. 26141.
3. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. 2014. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59:318-327. http://dx.doi.org/10.1002/hep. 26744.
4. Bukh J. 1995. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 15:41-63. http://dx.doi.org/10.1055/s-2007-1007262.
5. Okamoto H, Kojima M, Okada S, Yoshizwa H, Iizuka H, Tanaka T, Muchmore EE, Peterson DA, Ito Y, Mishiro S. 1992. Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology 190:894-899. http://dx.doi.org/10.1016/0042-6822 (92) 90933-G.
6. Mangia A, Santoro R, Minerva N, Ricci GL, Caretta V, Persico M, Vinelli F, Scotto G, Bacca D, Annese M, Romano M, Zechini F, Sogari F, Spirito F, Andriulli A. 2005. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 352:2609-2617. http://dx.doi.org/10.1056/NEJMoa042608.
7. Pang PS, Planet PJ, Glenn JS. 2009. The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. PLoS One 4:e6579. http://dx.doi.org/10.1371/journal.pone.0006579.
8. Zein NN. 2000. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 13:223-235. http://dx.doi.org/10.1128/CMR.13.2.223-235.2000.
9. AASLD/ISDA HCV Guidance Panel. 2015. Hepatitis C guidance: AASLD-ISDA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62:932-954. http://dx.doi.org/10.1002/hep. 27950.
10. European Association for the Study of the Liver. 2015. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 63:199-236. http://dx.doi.org/10.1016/j.jhep. 2015.03.025.
11. Bartenschlager R, Lohmann V, Penin F. 2013. The molecular and structural basis of advanced antiviral therapy for hepatitisCvirus infection. Nat Rev Microbiol 11:482-496. http://dx.doi.org/10.1038/nrmicro3046.
12. Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P. 2016. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int 36:47-57. http://dx.doi.org/10.1111/liv. 13027.
13. López-Labrador FX, Moya A, González-Candelas F. 2008. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antivir Ther 13:481-494.
14. Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T, Tigges AM, Adiwijaya BS, Lin C, Kwong AD, Kieffer TL. 2008. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3-4A protease inhibitors in treatment-naive subjects. J Infect Dis 198:800-807. http://dx.doi.org/10.1086/591141.
15. Paolucci S, Fiorina L, Piralla A, Gulminetti R, Novati S, Barbarini G, Sacchi P, Gatti M, Dossena L, Baldanti F. 2012. Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients. Virol J 9:245. http://dx.doi.org/10.1186/1743-422X-9-245.
16. Alves R, Queiro AT, Pessoa MG, da Silva EF, Mazo DF, Carrilho FJ, Carvalho-Filho RJ, de Carvalho IM. 2013. The presence of resistance mutations to protease and polymerase inhibitors in hepatitis C virus sequences from the Los Alamos databank. J Viral Hepat 20:414-421. http://dx.doi.org/10.1111/jvh.12051.
17. Paolucci S, Fiorina L, Mariani B, Gulminetti R, Novati S, Barbarini G, Bruno R, Baldanti F. 2013. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatmentnaïve patients. Virol J 10:355. http://dx.doi.org/10.1186/1743-422X-10-355.
18. de Carvalho IM, Alves R, de Souza PA, da Silva EF, Mazo D, Carrilho FJ, Queiroz AT, Pessoa MG. 2014. Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: novel insights about targeted genotyping approaches. J Med Virol 86:1714-1721. http://dx.doi.org/10.1002/jmv. 24015.
19. Margeridon-Thermet S, Le Pogam S, Li L, Liu TF, Shulman N, Shafer RW, Najera I. 2014. Similar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencing. PLoS One 9:e105569. http://dx.doi.org/10.1371/journal.pone.0105569.
20. Di Maio VC, Cento V, Mirabelli C, Artese A, Costa G, Alcaro S, Perno CF, Ceccherini-Silberstein F. 2014. Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors. Antimicrob Agents Chemother 58:2781-2797. http://dx.doi.org/10.1128/AAC.02386-13.
21. McCloskey RM, Liang RH, Joy JB, Krajden M, Montaner JS, Harrigan PR, Poon AF. 2015. Global origin and transmission of hepatitis C virus nonstructural protein 3 Q80K polymorphism. J Infect Dis 211:1288-1295. http://dx.doi.org/10.1093/infdis/jiu613.
22. Cento V, Mirabelli C, Salpini R, Dimonte S, Artese A, Costa G, Mercurio F, Svicher V, Parrotta L, Bertoli A, Ciotti M, Di Paolo D, Sarrecchia C, Andreoni M, Alcaro S, Angelico M, Perno CF, Ceccherini-Silberstein F. 2012. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS One 7:e39652. http://dx.doi.org/10.1371/journal.pone.0039652.
23. Combet C, Garnier N, Charavay C, Grando D, Crisan D, Lopez J, Dehne-Garcia A, Geourjon C, Bettler E, Hulo C, Le Mercier P, Bartenschlager R, Diepolder H, Moradpour D, Pawlotsky JM, Rice CM, Trepo C, Penin F, Deleage G. 2007. The European hepatitis C virus database. Nucleic Acids Res 35 (Database Issue):D363-D366.
24. Kuiken C, Yusim K, Boykin L, Richardson R. 2005. The Los Alamos HCVsequence database. Bioinformatics 21:379-384. http://dx.doi.org/10.1093/bioinformatics/bth485.
25. Pickett B, Greer D, Zhang Y, Stewart L, Zhou L, Sun G, Gu Z, Kumar S, Zaremba S, Larsen C, Jen W, Klem E, Scheuermann R. 2012. Virus Pathogen Database and Analysis Resource (ViPR): a comprehensive bioinformatics database and analysis resource for the coronavirus research community. Viruses 4:3209-3226. http://dx.doi.org/10.3390/v4113209.
26. Edgar RC. 2004. MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC Bioinformatics 5:113. http://dx.doi.org/10.1186/1471-2105-5-113.
27. Edgar RC. 2004. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 32:1792-1797. http://dx.doi.org/10.1093/nar/gkh340.
28. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony. Methods Mol Biol Evol 28:2731-2739. http://dx.doi.org/10.1093/molbev/msr121.
29. Huang Y, Niu B, Gao Y, Fu L, Li W. 2010. CD-HIT Suite: a Web server for clustering and comparing biological sequences. Bioinformatics 26:680-682. http://dx.doi.org/10.1093/bioinformatics/btq003.
30. Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. 2010. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol 59:307-321. http://dx.doi.org/10.1093/sysbio/syq010.
31. Salvatierra KA. 2014. Ph. D. thesis. University of Valencia, Valencia, Spain.
32. Hall TA. 1999. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 41:95-98.
33. R Core Team. 2014. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/.
34. Korber B, Myers G. 1992. Signature pattern analysis: a method for assessing viral sequence relatedness. AIDS Res Hum Retroviruses 8:1549-1560. http://dx.doi.org/10.1089/aid.1992.8.1549.
35. Excoffier L, Lischer HE. 2010. Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows. Mol Ecol Resour 10:564-567. http://dx.doi.org/10.1111/j.1755-0998.2010.02847.x.
36. Van de Vijver DA, Wensing AM, Angarano G, Asjö B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kücherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stöckl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CA. 2006. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 41:352-360. http://dx.doi.org/10.1097/01.qai.0000209899.05126.e4.
37. Svicher V, Cento V, Salpini R, Mercurio F, Fraune M, Beggel B, Han Y, Gori C, Wittkop L, Bertoli A, Micheli V, Gubertini G, Longo R, Romano S, Visca M, Gallinaro V, Marino N, Mazzotta F, De Sanctis GM, Fleury H, Trimoulet P, Angelico M, Cappiello G, Zhang XX, Verheyen J, Ceccherini-Silberstein F, Perno CF. 2011. Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development. Dig Liver Dis 43:975-983. http://dx.doi.org/10.1016/j.dld.2011.07.002.
38. Wyles DL, Gutierrez JA. 2014. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy. J Viral Hepat 21:229-240. http://dx.doi.org/10.1111/jvh.12230.
39. Svarovskaia ES, Dvory-Sobol H, Gontcharova V, Chiu S, Hebner CM, Hyland R, Kowdley K, Lawitz E, Gane E, Symonds WT, McHutchison JG, Miller MD, Mo H. 2012. Comprehensive resistance testing in patients who relapsed after treatment with sofosbuvir (GS-7977)-containing regimens in phase 2 studies. Hepatology 56(Suppl 1):551A.
40. Tong X, Li L, Haines K, Najera I. 2014. Identification of the NS5B S282T resistant variant and two novel amino acid substitutions that affect replication capacity in hepatitis C virus-infected patients treated with mericitabine and danoprevir. Antimicrob Agents Chemother 58:3105-3114. http://dx.doi.org/10.1128/AAC.02672-13.
41. McPhee F, Hernandez D, Yu F, Ueland J, Monikowski A, Carifa A, Falk P, Wang C, Fridell R, Eley T, Zhou N, Gardiner D. 2013. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology 58:902-911. http://dx.doi.org/10.1002/hep. 26388.
42. Legrand-Abravanel F, Henquell C, Le Guillou-Guillemette H, Balan V, Mirand A, Dubois M, Lunel-Fabiani F, Payan C, Izopet J. 2009. Naturally occurring substitutions conferring resistance to hepatitis C virus polymerase inhibitors in treatment-naive patients infected with genotypes 1-5. Antivir Ther 14:723-730.
43. Thibeault D, Bousquet C, Gingras R, Lagacé L, Maurice R, White PW, Lamarre D. 2004. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061. J Virol 78:7352-7359. http://dx.doi.org/10.1128/JVI.78.14.7352-7359.2004.
44. Scheel TK, Gottwein JM, Mikkelsen LS, Jensen TB, Bukh J. 2011. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α. Gastroenterology 140:1032-1042. http://dx.doi.org/10.1053/j.gastro.2010.11.036.
45. Sarrazin C, Zeuzem S. 2010. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138:447-462. http://dx.doi.org/10.1053/j.gastro.2009.11.055.